监管-话题@MedSci

#监管#

298篇内容 | 4563人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1371685, encodeId=181113e1685c8, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, objectTitle=医保基金持续承压，如何做好事前、事中监管？, objectType=article, longId=198834, objectId=336f198834dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=336f198834dd, replyNumber=0, likeNumber=60, createdTime=2020-08-07, rootId=0, userName=wwzzly, userId=b96f328, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=336f198834dd, moduleTitle=医保基金持续承压，如何做好事前、事中监管？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=336f198834dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1371684, encodeId=fb1f13e16845a, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, objectTitle=国家医保局解读：医保基金监管制度体系改革要完善哪些保障措施？, objectType=article, longId=197534, objectId=04c119e5342c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04c119e5342c, replyNumber=0, likeNumber=66, createdTime=2020-07-16, rootId=0, userName=wwzzly, userId=b96f328, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04c119e5342c, moduleTitle=国家医保局解读：医保基金监管制度体系改革要完善哪些保障措施？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04c119e5342c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1371683, encodeId=3b4613e168370, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, objectTitle=新冠肺炎疫情防控常态化下，实验室生物安全监管要做到这四点！, objectType=article, longId=197491, objectId=68e519e49132, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68e519e49132, replyNumber=0, likeNumber=78, createdTime=2020-07-15, rootId=0, userName=wwzzly, userId=b96f328, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68e519e49132, moduleTitle=新冠肺炎疫情防控常态化下，实验室生物安全监管要做到这四点！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68e519e49132)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1371682, encodeId=d0a113e16825e, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, objectTitle=国务院发文，医疗保障基金监管制度体系迎巨变, objectType=article, longId=197355, objectId=9fbb19e355c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fbb19e355c7, replyNumber=0, likeNumber=76, createdTime=2020-07-12, rootId=0, userName=wwzzly, userId=b96f328, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fbb19e355c7, moduleTitle=国务院发文，医疗保障基金监管制度体系迎巨变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fbb19e355c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1371681, encodeId=a0c713e16817c, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, objectTitle=国家药监局：落实药品、医疗器械等“四个严格”监管要求，对违法违规行为“处罚到人”, objectType=article, longId=196042, objectId=d5cc19604262, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5cc19604262, replyNumber=0, likeNumber=68, createdTime=2020-06-19, rootId=0, userName=wwzzly, userId=b96f328, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5cc19604262, moduleTitle=国家药监局：落实药品、医疗器械等“四个严格”监管要求，对违法违规行为“处罚到人”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5cc19604262)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1371680, encodeId=613313e1680a3, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, objectTitle=欧盟监管机构开始审查LEO的IL-13单抗tralokinumab，治疗特应性皮炎, objectType=article, longId=195833, objectId=7404195833c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7404195833c3, replyNumber=0, likeNumber=103, createdTime=2020-06-15, rootId=0, userName=wwzzly, userId=b96f328, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7404195833c3, moduleTitle=欧盟监管机构开始审查LEO的IL-13单抗tralokinumab，治疗特应性皮炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7404195833c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1371679, encodeId=d7a413e16798b, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, objectTitle=上海医保监管新规实施打击欺诈骗保还需“内外兼修”, objectType=article, longId=195141, objectId=2d7919514143, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d7919514143, replyNumber=0, likeNumber=94, createdTime=2020-06-03, rootId=0, userName=wwzzly, userId=b96f328, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d7919514143, moduleTitle=上海医保监管新规实施打击欺诈骗保还需“内外兼修”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d7919514143)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1371678, encodeId=545d13e1678ce, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, objectTitle=诊所、门诊部注意！医保计分制监管来了, objectType=article, longId=194397, objectId=d1e619439efa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1e619439efa, replyNumber=0, likeNumber=65, createdTime=2020-05-21, rootId=0, userName=wwzzly, userId=b96f328, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1e619439efa, moduleTitle=诊所、门诊部注意！医保计分制监管来了, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1e619439efa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1371677, encodeId=4bf213e167771, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, objectTitle=欧洲监管机构批准治疗间变性大细胞淋巴瘤的靶向药物--武田抗CD30的ADC药物Adcetris, objectType=article, longId=194236, objectId=13fa194236c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13fa194236c3, replyNumber=0, likeNumber=65, createdTime=2020-05-17, rootId=0, userName=wwzzly, userId=b96f328, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13fa194236c3, moduleTitle=欧洲监管机构批准治疗间变性大细胞淋巴瘤的靶向药物--武田抗CD30的ADC药物Adcetris, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13fa194236c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1371676, encodeId=16ee13e167616, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, objectTitle=七部门发文：着重对口罩、额温枪等五类防疫物资加强监管, objectType=article, longId=194108, objectId=b1831941089f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1831941089f, replyNumber=0, likeNumber=71, createdTime=2020-05-15, rootId=0, userName=wwzzly, userId=b96f328, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1831941089f, moduleTitle=七部门发文：着重对口罩、额温枪等五类防疫物资加强监管, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1831941089f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1371675, encodeId=849713e167536, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, objectTitle=印度监管机构：批准Favipiravir抗病毒片剂治疗COVID-19的临床试验, objectType=article, longId=193368, objectId=16431933689c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16431933689c, replyNumber=0, likeNumber=60, createdTime=2020-05-03, rootId=0, userName=wwzzly, userId=b96f328, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16431933689c, moduleTitle=印度监管机构：批准Favipiravir抗病毒片剂治疗COVID-19的临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16431933689c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1371674, encodeId=9a9c13e1674d5, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, objectTitle=市场监管总局发布《个人健康信息码》系列国家标准, objectType=article, longId=193358, objectId=5ba41933589b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ba41933589b, replyNumber=0, likeNumber=73, createdTime=2020-05-03, rootId=0, userName=wwzzly, userId=b96f328, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ba41933589b, moduleTitle=市场监管总局发布《个人健康信息码》系列国家标准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ba41933589b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1371673, encodeId=37f413e1673b6, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, objectTitle=德国监管机构批准COVID-19疫苗的临床计划, objectType=article, longId=192834, objectId=632619283481, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=632619283481, replyNumber=0, likeNumber=67, createdTime=2020-04-25, rootId=0, userName=wwzzly, userId=b96f328, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=632619283481, moduleTitle=德国监管机构批准COVID-19疫苗的临床计划, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=632619283481)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1371672, encodeId=259413e16726a, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, objectTitle=Astellas宣布其FLT3抑制剂XOSPATA治疗白血病，正在NMPA接受监管审查, objectType=article, longId=192019, objectId=85d919201914, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85d919201914, replyNumber=0, likeNumber=77, createdTime=2020-04-13, rootId=0, userName=wwzzly, userId=b96f328, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85d919201914, moduleTitle=Astellas宣布其FLT3抑制剂XOSPATA治疗白血病，正在NMPA接受监管审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85d919201914)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1371671, encodeId=7d2613e1671c5, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, objectTitle=百时美施贵宝宣布，美国与欧洲监管机构已接受欧狄沃（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗用于肺癌一线治疗的申请, objectType=article, longId=191924, objectId=e2a4191924a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e2a4191924a2, replyNumber=0, likeNumber=54, createdTime=2020-04-11, rootId=0, userName=wwzzly, userId=b96f328, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e2a4191924a2, moduleTitle=百时美施贵宝宣布，美国与欧洲监管机构已接受欧狄沃（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗用于肺癌一线治疗的申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e2a4191924a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1371670, encodeId=c39113e167091, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, objectTitle=试行跨区域监管，“长三角医疗器械注册人制度”又迈出一步, objectType=article, longId=189801, objectId=f4b4189801d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4b4189801d2, replyNumber=0, likeNumber=60, createdTime=2020-03-13, rootId=0, userName=wwzzly, userId=b96f328, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4b4189801d2, moduleTitle=试行跨区域监管，“长三角医疗器械注册人制度”又迈出一步, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4b4189801d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1371669, encodeId=e81913e166901, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, objectTitle=从招标规则的变化来看监管方对国家集采的态度, objectType=article, longId=186403, objectId=7a78186403e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a78186403e1, replyNumber=0, likeNumber=56, createdTime=2020-01-18, rootId=0, userName=wwzzly, userId=b96f328, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a78186403e1, moduleTitle=从招标规则的变化来看监管方对国家集采的态度, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a78186403e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1371668, encodeId=7da113e166836, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, objectTitle=“网红”百万医疗险套路太多监管要出手整顿了, objectType=article, longId=185966, objectId=a88b185966f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a88b185966f0, replyNumber=0, likeNumber=63, createdTime=2020-01-10, rootId=0, userName=wwzzly, userId=b96f328, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a88b185966f0, moduleTitle=“网红”百万医疗险套路太多监管要出手整顿了, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a88b185966f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1371667, encodeId=b83413e16671b, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, objectTitle=“水滴筹”“轻松筹”“爱心筹”，网络众筹平台如何监管？, objectType=article, longId=184694, objectId=e4ab1846941a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4ab1846941a, replyNumber=0, likeNumber=62, createdTime=2019-12-14, rootId=0, userName=wwzzly, userId=b96f328, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4ab1846941a, moduleTitle=“水滴筹”“轻松筹”“爱心筹”，网络众筹平台如何监管？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4ab1846941a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1371666, encodeId=949f13e1666a9, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, objectTitle=监管空白！在线买处方药吃死人英国紧急查处16家线上药房, objectType=article, longId=184690, objectId=6757184690c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6757184690c2, replyNumber=0, likeNumber=80, createdTime=2019-12-14, rootId=0, userName=wwzzly, userId=b96f328, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6757184690c2, moduleTitle=监管空白！在线买处方药吃死人英国紧急查处16家线上药房, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6757184690c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

监管

2020-05-29

wwzzly (审核中...)

前往app查看评论内容

#监管#

医保基金持续承压，如何做好事前、事中监管？

2020-08-07

wwzzly (审核中...)

前往app查看评论内容

#监管#

国家医保局解读：医保基金监管制度体系改革要完善哪些保障措施？

2020-07-16

wwzzly (审核中...)

前往app查看评论内容

#监管#

新冠肺炎疫情防控常态化下，实验室生物安全监管要做到这四点！

2020-07-15

wwzzly (审核中...)

前往app查看评论内容

#监管#

国务院发文，医疗保障基金监管制度体系迎巨变

2020-07-12

wwzzly (审核中...)

前往app查看评论内容

#监管#

国家药监局：落实药品、医疗器械等“四个严格”监管要求，对违法违规行为“处罚到人”

2020-06-19

wwzzly (审核中...)

前往app查看评论内容

#监管#

欧盟监管机构开始审查LEO的IL-13单抗tralokinumab，治疗特应性皮炎

2020-06-15

wwzzly (审核中...)

前往app查看评论内容

#监管#

上海医保监管新规实施打击欺诈骗保还需“内外兼修”

2020-06-03

wwzzly (审核中...)

前往app查看评论内容

#监管#

诊所、门诊部注意！医保计分制监管来了

2020-05-21

wwzzly (审核中...)

前往app查看评论内容

#监管#

欧洲监管机构批准治疗间变性大细胞淋巴瘤的靶向药物--武田抗CD30的ADC药物Adcetris

2020-05-17

wwzzly (审核中...)

前往app查看评论内容

#监管#

七部门发文：着重对口罩、额温枪等五类防疫物资加强监管

2020-05-15

wwzzly (审核中...)

前往app查看评论内容

#监管#

印度监管机构：批准Favipiravir抗病毒片剂治疗COVID-19的临床试验

2020-05-03

wwzzly (审核中...)

前往app查看评论内容

#监管#

市场监管总局发布《个人健康信息码》系列国家标准

2020-05-03

wwzzly (审核中...)

前往app查看评论内容

#监管#

德国监管机构批准COVID-19疫苗的临床计划

2020-04-25

wwzzly (审核中...)

前往app查看评论内容

#监管#

Astellas宣布其FLT3抑制剂XOSPATA治疗白血病，正在NMPA接受监管审查

2020-04-13

wwzzly (审核中...)

前往app查看评论内容

#监管#

百时美施贵宝宣布，美国与欧洲监管机构已接受欧狄沃（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗用于肺癌一线治疗的申请

2020-04-11

wwzzly (审核中...)

前往app查看评论内容

#监管#

试行跨区域监管，“长三角医疗器械注册人制度”又迈出一步

2020-03-13

wwzzly (审核中...)

前往app查看评论内容

#监管#

从招标规则的变化来看监管方对国家集采的态度

2020-01-18

wwzzly (审核中...)

前往app查看评论内容

#监管#

“网红”百万医疗险套路太多监管要出手整顿了

2020-01-10

wwzzly (审核中...)

前往app查看评论内容

#监管#

“水滴筹”“轻松筹”“爱心筹”，网络众筹平台如何监管？

2019-12-14

wwzzly (审核中...)

前往app查看评论内容

#监管#

监管空白！在线买处方药吃死人英国紧急查处16家线上药房

2019-12-14

科室
- - 订阅+
  - 更多科室
工具
服务